Brad Snow is President and CEO of Angel Medical Systems, Inc. AngelMed’s flagship product, The Guardian System is the world first and only FDA approved real-time implantable cardiac device to detect ACS events, including silent heart attacks.
Brad has been a member of AngelMed’s Board of Directors since early 2019 and is a seasoned med-tech executive with 25 years’ experience in start-ups and emerging growth companies
Brad’s most recent role was CEO and Board of Director Sonacare Medical (now Sonablate Corp) where he led the organization through several strategic initiatives, inclusive of a significant multiyear sales agreement.
Prior to Sonacare, Brad was Vice President of Sales and Marketing at BTG plc where he led 3 of their 4 commercial divisions experiencing hypergrowth. BTG plc was acquired in January 2020 for $4.2 billion by Boston Scientific.
His previous leadership experience ranges from CEO to Commercial leadership roles at SurgiTrac, ARAGON Surgical, Rubicor Medical, Fox Hollow Technologies, and RITA Medical Systems.
Brad is a native of St. Louis, MO and is a graduate of the University of Missouri.
